Summary and considerations in genitourinary cancer patient care during the COVID-19 pandemic

ABSTRACT Purpose: To provide a summary and recommendations for the set-up of strategies for cancer patients care in genitourinary oncology clinics during the pandemic and in the recovery period. Material and Methods: A non-systematic review of available literature on the management of urological malignancies during the COVID-19 pandemic was performed to summarize recommendations to improve the diagnosis and treatment of urological cancers during and after the contingence, including clinical and research aspects. Results: Urological cancer diagnosis and management should be tailored according to the severity of the COVID-19 crisis in each region and the aggressiveness of each tumor. Clinicians should adhere to strict protocols in order to prioritize the attention of patients with high-risk malignancies while optimizing resources to avoid the saturation of critical care services. Conclusions: During the COVID-19 pandemic urological cancer care has been severely impaired. For proper patient management, multidisciplinary approach is encouraged tailoring therapy according to COVID-19 regional behavior and local institutional resources. Patients with high-risk malignancies should be prioritized.

Incidence and treatment of malignant tumors of the genitourinary tract in renal transplant recipients

ABSTRACT Purpose: To provide data of the incidence and management of common urological malignancies in renal transplant recipients. Materials and Methods: We conducted a retrospective analysis of a prospective database from August 1967 to August 2015. A descriptive analysis of the sample was performed. Results: Among 1256 consecutive RTR a total of 88 patients developed malignancies (7%). There were 18 genitourinary tumors in the 16 patients (20.45 % of all malignant neoplasms), incidence of 1.27%. The most common neoplasm encounter was renal cancer (38.8%), followed by urothelial carcinoma (33.3%). Median follow-up of transplantation was 197 months (R, 36-336). Mean time from RT to cancer diagnosis 89±70 months (R, 12-276). CsA and AZA was the most common immunosuppression regimen in 68.75%. Mean follow-up after diagnosis was 103±72 months (R 10-215). Recurrence free survival rate of 100%. Overall survival of 89.5% of the sample; there were two non-related cancer deaths during follow-up. Conclusions: The incidence of neoplasms in RTR was lower than in other series, with favorable functional and oncologic results after treatment. This suggests that actions to reduce the risk of these malignancies as well as a strict follow-up are mandatory for an early detection and treatment.

Male Genitourinary Tumors : 14 Years Experience in Garhwal Region of India.

Genitourinary tumors may show varied clinical presentation and frequency in different regions of the world. The present study was therefore conducted to analyze the frequency, clinical presentation and the histopathological types of the various male genitourinary tumors diagnosed over a period of 14 years in a major teaching institute of north Himalayan region of India. Material and Methods: Retrospective study was undertaken in the Pathology department of the Institute which included all the cases of male genitourinary tumors which were diagnosed on histopathology from the time period between 1 Jan 1997 till 31st Dec. 2010. Results: The study showed that prostate was the most common site for male genitourinary tumors with prostatic adenocarcinoma as the most common histopathological type of tumor. Testicular Non- Hodgkin’s lymphoma constituted about 8% of total tumors in testes which mostly presented in elderly age group. Renal cell carcinoma (66.2%) was the most common tumor in kidney with much lower frequency of Wilm’s tumor (16.9%). Occasional rare tumors such as hemangioma of urinary bladder and schwannoma of penis were also seen over 14 years. Conclusion: The study concludes clinically patients were associated with more severe symptoms as they presented late to the hospital from the remote areas of this Himalayan region leading to late detection of tumors. Prostatic adenocarcinoma was the most common tumor while renal cell carcinoma was most common tumor in kidney. The present study provides valuable information to clinicians and pathologists regarding frequency, clinical presentation and histopathological types of male genitourinary tumors in this region which can be further used to formulate strategies for better management of these tumors.

Melanoma de mucosa oral, genital e anorretal / Melanoma of oral, genital and anorectal mucous membrane

Entre 1970 e 1997, 411 pacientes com diagnóstico de melanoma foram atendidos no Hospital São Judas Tadeu de Barretos. Destes, 7 (1,7 porcento) eram de mucosa e os respectivos prontuários foram analisados para este trabalho. Quanto à localização, eram anorretal; 2 eram vulvovaginal, e 1 localizava-se no palato; havia seis pacientes do sexo feminino e um masculino variando as idades de 31 a 81 anos (média= 61 anos). Apenas um paciente apresentou tumor localizado (está com quase 5 anos de sobrevida), 4 tinham doença regional (todos faleceram antes de 3 anos após o diagnóstico) e dois tinham metástases (óbitos ocorridos antes de um ano após diagnóstico). Os tratamentos variaram de conformidade com o estadiamento da doença. Os dados evidenciam o prognóstico ruim da moléstia, que se apresenta, usualmente em estádios avançados e, freqüentemente, com metástases.

Novedades en el diagnóstico y tratamiento del cáncer urogenital / News in diagnostic and treatment of urogenital cancer

Es necesario actualizar periódicamente los progresos obtenidos en la urología oncológica. Los avances de la tecnología moderna aplicados a la medicina y en particular a la urología, nos permiten actualmente una mayor presión en el diagnóstico y tratamiento de la neoplasias urológicas. La investigación básica sobre el origen de los tumores urológicos ha dado valor al concepto de que los cánceres pueden ser producidos por la acción de virus oncógenos sobre células normales del organismo. Los marcadores bioquímicos tumorales, la citologia urinaria y el progreso tecnológico de la endoscopia, la radiología, el empleo de nuevas drogas, contribuyen espectacularmente en la actualidad al diagnóstico y tratamiento de la neoplasias urogenitales. Se revisan los progresos importantes obtenidos en los tumores del riñón, vejiga, prostata y testiculo